

## A-Kinase-Anchoring Protein (AKAP150) is expressed in Astrocytes and Upregulated in Response to Ischemia

Aixa F. Rivera-Pagán,<sup>a</sup> Miguel P. Méndez-González,<sup>a,f</sup> David E. Rivera-Aponte,<sup>a</sup> Christian J. Malpica-Nieves,<sup>a</sup> Katya V. Melnik-Martínez,<sup>b</sup> Astrid Zayas-Santiago,<sup>c</sup> Gerónimo Maldonado-Martínez,<sup>d</sup> Yaroslav M. Shuba,<sup>e</sup> Serguei N. Skatchkov<sup>a,b\*</sup> and Misty J. Eaton<sup>a\*</sup>

<sup>a</sup> Department of Biochemistry, Universidad Central del Caribe, Bayamón, PR, United States

<sup>b</sup> Department of Physiology, Universidad Central del Caribe, Bayamón, PR, United States

<sup>c</sup> Department of Pathology and Laboratory Medicine, Universidad Central del Caribe, Bayamón, PR, United States

<sup>d</sup> Retrovirus Research Center, Universidad Central del Caribe, Bayamón, PR, United States

<sup>e</sup> Bogomoletz Institute of Physiology and International Center of Molecular Physiology of the National Academy of Sciences of Ukraine, Kiev, Ukraine

<sup>f</sup> University of Puerto Rico, Natural Sciences Department, Aguadilla, PR, United States

**Abstract—A-kinase-anchoring proteins, AKAPs, are scaffolding proteins that associate with kinases and phosphatases, and direct them to a specific submembrane site to coordinate signaling events. AKAP150, a rodent ortholog of human AKAP79, has been extensively studied in neurons, but very little is known about the localization and function of AKAP150 in astrocytes, the major cell type in brain. Thus, in this study, we assessed the localization of AKAP150 in astrocytes and elucidated its role during physiological and ischemic conditions. Herein, we demonstrate that AKAP150 is localized in astrocytes and is up-regulated during ischemia both *in vitro* and *in vivo*. Knock-down of AKAP150 by RNAi depolarizes the astrocytic membrane potential and substantially reduces by 80% the ability of astrocytes to take up extracellular potassium during ischemic conditions. Therefore, upregulation of AKAP150 during ischemia preserves potassium conductance and the associated hyperpolarized membrane potential of astrocytes; properties of astrocytes needed to maintain extracellular brain homeostasis. Taken together, these data suggest that AKAP150 may play a pivotal role in the neuroprotective mechanism of astrocytes during pathological conditions. © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.**

**Key words:** potassium uptake, membrane potential, middle cerebral artery occlusion, siRNA, cortical astrocytes.

### INTRODUCTION

A-kinase-anchoring proteins (AKAPs) are scaffolding proteins that recruit and direct protein kinases and phosphatases to a specific submembrane site and contribute to the regulation of phosphorylation events (Michel and Scott, 2002; Carnegie et al., 2009). Many studies have focused on the localization and role of AKAPs in brain, specifically the role of AKAP150 in neurons (Rosenmund et al., 1994; Carnegie and Scott, 2003; Snyder et al., 2005; Chen and Kass, 2005;

Dell'Acqua et al., 2006; Zhang et al., 2011). In neurons, AKAP150 has been extensively described in *in vivo* and *in vitro* model systems (Rosenmund et al., 1994; Carnegie and Scott, 2003; Snyder et al., 2005; Chen and Kass, 2005; Dell'Acqua et al., 2006; Schnizler et al., 2008; Zhang et al., 2011; Jeske et al., 2011). Histologically AKAP150 along with the human homolog AKAP79 have been described in neuronal density fractions, cell bodies and dendrites (Sandoz et al., 2006; Lilly et al., 2005; Glantz et al., 1992; Carr et al., 1992; Klauck et al., 1996; Dell'Acqua et al., 1998; Sik et al., 2000; Gomez et al., 2002). Accumulating evidence demonstrates that these AKAPs associate with kinases and phosphatases and direct them to a specific subcellular compartment and modulate NMDAR, AMPAR, Kir2.1, TREK, TASK, TRP and other ion channel activity in neurons (Rosenmund et al., 1994; Dart and Leyland, 2001; Gomez et al., 2002; Sandoz et al., 2006; Schnizler et al., 2008; Zhang et al., 2011; Jeske et al., 2011; Efendiev et al., 2013).

\*Corresponding authors. Address: Department of Biochemistry, Universidad Central del Caribe, P.O. Box 60327, Bayamón, PR 00960-6032, United States (S. Skatchkov). Department of Biochemistry, Universidad Central del Caribe, P.O. Box 60327, Bayamón, PR 00960-6032, United States (M.J. Eaton). Fax: +1-(787)-786-6285. E-mail addresses: [serguei.skatchkov@ucaribe.edu](mailto:serguei.skatchkov@ucaribe.edu) (S. N. Skatchkov), [misty.eaton@ucaribe.edu](mailto:misty.eaton@ucaribe.edu) (M. J. Eaton).  
**Abbreviations:** AKAP, A-Kinase-Anchoring Protein; BBSS, bicarbonate-buffered balanced salt solution; tMCAO, transient middle cerebral artery occlusion.

47 Despite the many advances in understanding the role  
48 of AKAP150 in neurons, there is a lack of knowledge  
49 about AKAP150 function in astrocytes. While given the  
50 anatomical location and abundance of astrocytes in  
51 cortex, in the literature, a single microscopy study was  
52 found showing AKAP150 immunoreactivity within glia  
53 (Lilly et al., 2005). However, it was a descriptive observa-  
54 tion and the significance of their finding has yet to be  
55 determined. Therefore, the presence of AKAP150 in  
56 astrocytes and its importance during physiological and  
57 pathological conditions remains unknown. The goal of  
58 the present study was to address these questions both  
59 *in vitro* and *in vivo* by examining the localization of  
60 AKAP150 in astrocytes and assessing the role of  
61 AKAP150 on one of the key astrocytic functions, potas-  
62 sium uptake, during normal and pathophysiological  
63 ischemic conditions. Here we show that astrocytes  
64 express AKAP150 which is upregulated during ischemia  
65 and maintains potassium conductance and the associ-  
66 ated hyperpolarized membrane potential of astrocytes.

## 67 EXPERIMENTAL PROCEDURES

### 68 Animals

69 Experiments were carried out in accordance with a  
70 protocol approved by the Universidad Central del Caribe  
71 Institutional Animal Care and Use Committee. Adequate  
72 measures were taken to minimize pain or discomfort of  
73 experimental animals. Postnatal 1–2 day old Sprague–  
74 Dawley rats were used for preparing primary astrocytes  
75 cultures and adult Sprague–Dawley rats (250–300 g)  
76 were used for transient middle cerebral artery occlusion  
77 (tMCAO) experiments.

### 78 Astrocyte primary cultures

79 Primary cortical astrocyte cultures were prepared from  
80 neocortex of 1- to 2-day-old rats as previously described  
81 (Kucheryavykh et al., 2007).

### 82 Simulated ischemia

83 Astrocytes were exposed to hypoxia/hypoglycemia  
84 conditions for 24 h to simulate ischemia *in vitro* as  
85 previously described in Rivera-Pagán et al. (2015).  
86 Briefly, astrocytes were plated in petri dishes and to  
87 achieve hypoxia/hypoglycemic conditions the medium  
88 from cultures was removed, cells were gently rinsed and  
89 a bicarbonate-buffered balanced salt solution (BBSS)  
90 containing: 127 mM NaCl, 3 mM KCl, 19.5 mM NaHCO<sub>3</sub>,  
91 1.5 mM NaH<sub>2</sub>PO<sub>4</sub>, 1.4 mM MgSO<sub>4</sub>, 1 mM CaCl<sub>2</sub> and  
92 2.5 mM D-glucose and previously gassed with 5 min of  
93 95%N<sub>2</sub> and 5%CO<sub>2</sub> was applied to the cells. Afterward,  
94 cells were placed in a chamber flooded with 95% N<sub>2</sub>  
95 and 5%CO<sub>2</sub> and incubated at 37 °C for 24 h. Control cells  
96 were incubated in a BBSS solution containing 25 mM  
97 D-glucose and incubated at 37 °C for 24 h under normoxic  
98 conditions (95%air and 5%CO<sub>2</sub>). We have previously  
99 shown using electrophysiological techniques that astro-  
100 cytes exposed to these conditions are viable  
101 (Kucheryavykh et al., 2009).

### RNA interference by small double-stranded RNAs

102 As we previously described (Kucheryavykh et al., 2007),  
103 the cells were transfected using HiPerfect transfection  
104 reagent (Qiagen, Germantown, MD, USA) and the Fast-  
105 Forward Protocol for Transfection of Adherent Cells with  
106 siRNA recommended by the manufacturer (Qiagen,  
107 S102000271). Briefly, 20 nM of siRNA-targeting  
108 AKAP150 and 12 μL of HiPerfect were diluted in 100 μL  
109 of culture medium without serum. The mix was incubated  
110 for 10 min at room temperature to allow the formation of  
111 transfection complexes. The complexes were then added  
112 to the cells in a drop-wise fashion giving a final volume of  
113 2 mL. The plate was gently swirled to evenly distribute the  
114 transfection complexes and cells were incubated at 37 °C  
115 for four days. Cell were either used for electrophysiological  
116 studies or harvested and AKAP 150 protein expres-  
117 sion was measured and compared in control (no  
118 transfection reagent), mock-transfected (transfection  
119 reagent (HiPerfect) without siRNA) and AKAP150 siRNA  
120 transfected astrocytes (transfection reagent (HiPerfect)  
121 with siRNA).  
122

### SDS–PAGE and western blotting analysis

123 Astrocytes were pelleted and resuspended in lysis buffer  
124 (pH 7.5) containing: (in mM) Tris–HCl 20, NaCl 150,  
125 EDTA 1.0, EGTA 1.0, PMSF 1.0, 1% Triton X-100, and  
126 an additional mixture of peptide inhibitors (leupeptin,  
127 bestatin, pepstatin, and aprotinin). Total protein of  
128 homogenates were determined with the Bradford protein  
129 assay (Bio-Rad), followed by addition of an appropriate  
130 volume of Urea sample buffer (62 mM Tris/HCl pH 6.8,  
131 4% SDS, 8 M Urea, 20 mM EDTA, 5%  
132 β-Mercaptoethanol, 0.015% Bromophenol Blue) to load  
133 15 μg of protein per lane. Next, samples were boiled in  
134 a water bath at 95 °C for 10 min, spun to pellet debris,  
135 and immediately run on 7% SDS–polyacrylamide gels.  
136 Western blotting was performed as previously described  
137 (Kucheryavykh et al., 2009) using rabbit polyclonal anti-  
138 bodies against AKAP150 (1:200; Santa Cruz Biotechnol-  
139 ogy, Dallas, TX, USA; Cat# sc-10765, RRID:  
140 AB\_2289482). Final detection was performed with  
141 enhanced chemiluminescence methodology (SuperSignal®  
142 West Dura Extended Duration Substrate; Pierce,  
143 Rockford, IL, USA) as described by the manufacturer,  
144 and the intensity of the signal was measured in a gel doc-  
145 umentation system (Versa Doc Model 1000, Bio Rad,  
146 Hercules, CA, USA). In all cases, intensity of the chemilu-  
147 minescence signal was corrected for minor differences in  
148 protein content after densitometry analysis of the India  
149 ink-stained membrane.  
150

### Patch-clamp electrophysiology: voltage and K+ steps

151 Membrane potentials and currents were measured with  
152 the single-electrode whole-cell patch-clamp technique.  
153 Two Narishige hydraulic micromanipulators (Narishige,  
154 MMW-203, Amityville, NY, USA) were used for (1)  
155 voltage-clamp recording, and (2) positioning a  
156 micropipette with 30- to 50-μm tip diameter for the  
157  
158

Download English Version:

<https://daneshyari.com/en/article/8840622>

Download Persian Version:

<https://daneshyari.com/article/8840622>

[Daneshyari.com](https://daneshyari.com)